Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jan;22(1):21-6.
doi: 10.1007/s00198-010-1274-6. Epub 2010 May 11.

Oral bisphosphonate compliance and persistence: a matter of choice?

Affiliations
Review

Oral bisphosphonate compliance and persistence: a matter of choice?

S L Silverman et al. Osteoporos Int. 2011 Jan.

Abstract

Compliance to oral bisphosphonates is suboptimal, with negative consequences of increased healthcare utilization and less effective fracture risk reduction. Extending dose interval increased adherence only moderately. We used literature derived from multiple chronic conditions to examine the problem of noncompliance with osteoporosis medication. We reviewed the literature on adherence to osteoporosis medication as well as that across multiple chronic conditions to understand what is known about the cause of the poor adherence. Poor compliance to oral medications is due mostly, not to forgetfulness, but to deliberate choice. Gender differences and style of healthcare management also play a role. Preliminary data suggest psychobehavioral interventions may help to improve motivation. We need to understand better reasons for poor compliance before effective interventions can be developed. Forgetfulness is only a small part of poor compliance. Patient preferences must be considered in medication decision making.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–1031. doi: 10.1007/s00198-006-0322-8. - DOI - PubMed
    1. Silverman SL, Cramer JA, Sunyecz JA, et al (2007) Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases. Presented at ASBMR Montreal, 19 Sept 2007. Abstract W366
    1. Cotte FE, Fardelione P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2009;29(1):125–139. - PMC - PubMed
    1. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin. 2006;22(12):2383–2391. doi: 10.1185/030079906X154042. - DOI - PubMed
    1. Gorai I, Tanaka Y, Hattori S, Iwaoki Y. Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene or alfacalcidol in postmenopausal Japanese women. J Bone Miner Metab. 2010;28:176–184. doi: 10.1007/s00774-009-0112-4. - DOI - PubMed

MeSH terms

Substances